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The development of transfection technology for ma-
laria parasites holds significant promise for a more de-
tailed characterization of molecules targeted by vac-
cines or drugs. One asexual blood stage vaccine
candidate, apical membrane antigen-1 (AMA-1) of mero-
zoite rhoptries has been shown to be the target of inhib-
itory, protective antibodies in both in vitro and in vivo
studies. We have investigated heterologous (trans-spe-
cies) expression of the human malaria Plasmodium fal-
ciparum AMA-1 (PF83/AMA-1) in the rodent parasite
Plasmodium berghei. Transfected P. berghei expressed
correctly folded and processed PF83/AMA-1 under con-
trol of both pb66/ama-1 and dhfr-ts promoters. Timing of
expression was highly promoter-dependent and was
critical for subsequent subcellular localization. Under
control of pb66/ama-1, PF83/AMA-1 expression and local-
ization in P. berghei was limited to the rhoptries of
mature schizonts, similar to that observed for PF83/
AMA-1 in P. falciparum. In contrast the dhfr-ts promoter
permitted PF83/AMA-1 expression throughout schizog-
ony as well as in gametocytes and gametes. Localization
was aberrant and included direct expression at the mer-
ozoite and gamete surface. Processing from the full-
length 83-kDa protein to a 66-kDa protein was observed
not only in schizonts but also in gametocytes, indicating
that processing could be mediated outside of rhoptries
by a common protease. Trans-species expressed PF83/
AMA-1 was highly immunogenic in mice, resulting in a
response against a functionally critical domain of the
molecule.
The protozoan parasite Plasmodium falciparum is a causa-
tive agent of malaria, one of the major human infectious dis-
eases. In the search for new methods to combat the disease, the
advent of transfection technology for Plasmodium species is
critical, because it offers the opportunity to relate genotype to
phenotype, and this will permit a more rational design of vac-
cines and drugs. To date, stable episomal maintenance of plas-
mid DNA introduced into Plasmodium has been reported (1–3)
as well as site-directed integration of DNA into the parasite
genome (4–8). This technology also offers the possibility to
dissect the thus far poorly characterized Plasmodium promoter
function (9–11) and study the relation between the tightly
controlled timing of expression and the subcellular trafficking
and localization of stage-specific proteins. Trans-species ex-
pression of malarial antigens will allow targeted development
of attenuated parasite vaccines and opens possibilities for
complementation of otherwise detrimental integration into es-
sential genes. Apical membrane antigen-1 (AMA-1)1 is an at-
tractive candidate for such studies, because it appears to be
intimately involved in red cell invasion (12). Expression and
post-translational N-terminal proteolytic cleavage of AMA-1
are restricted to the final stages of schizogony (13), during
which the protein is localized within the neck of the rhoptry, an
apical secretory organelle of the merozoite involved in red cell
invasion (14). AMA-1 is a major candidate for inclusion in a
malaria blood stage vaccine following in vivo experiments in
nonhuman primates and rodents showing that AMA-1 can
induce protective immune responses (15–17).
Here we report for the first time in a malaria parasite the
development of drug-selectable trans-species expression of a
second gene (in addition to the selectable marker) and its use to
investigate the role of the promoter on subcellular localization
of the trans-species expressed protein. P. falciparum AMA-1
(PF83/AMA-1) expression in the rodent malaria Plasmodium
berghei was driven by the stage-specific P. berghei AMA-1
promoter (pb66/ama-1) or the more constitutive P. berghei
dihydrofolate reductase-thymidylate synthase (dhfr-ts) pro-
moter. The type of promoter control determined the timing and
subsequent subcellular localization of PF83/AMA-1, which
markedly differed between the two promoters. In addition, the
trans-species expressed protein proved to be highly immuno-
genic in mice, resulting in antibodies to a critical functional
determinant of PF83/AMA-1.
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MATERIALS AND METHODS
DNA Constructs
The selection cassette controlling Toxoplasma gondii DHFR-TS ex-
pression and the pUC19 backbone (element pDB.DTm.DB., nomencla-
ture following Ref. 18) were common to all constructs used for trans-
fection and were as described previously for transfection of Plasmodium
knowlesi (3) except that Tg dhfr-ts (GenBanky accession number
L08489) was conservatively mutagenized (pAlter kit, Promega, Madi-
son, WI) to remove EcoRI and KpnI sites by use of oligonucleotides
ToxM1 CCATGAAGAGTTCCAGTAC (base pairs 3722–3741) and
ToxM2 CAACGGGGTTCCCTACGAC (base pairs 3064–3083), the al-
tered residue being underlined. Through a series of cloning steps plas-
mids pDB.DTm.DB./DB.AF.DB. and pDB.DTm.DB./AB.AF.DB. and two plas-
mids that were identical but for reversed orientation of pf83/ama-1
open reading frame (ORF) (pDB.DTm.DB./DB.a AF.DB. and pDB.DTm.DB./
AB.a AF.DB.) were derived (see Fig. 1). Pf83/ama-1 was base pairs
1–1869 (complete ORF) of P. falciparum 7G8 strain (19). 59 pb66 was a
1.5-kb polymerase chain reaction fragment lying immediately 59 to the
pb66/ama-1 ORF that had been amplified using sequence derived from
a lZAP P. berghei ANKA genomic library probed with pf83/ama-1.
Recombinant DNA manipulations and analyses were performed accord-
ing to standard procedures (20).
Derivation and Maintenance of Transfected Parasites
P. berghei ANKA clone 15cy1 schizonts derived from infected Wistar
rats were electroporated with constructs pDB.DTm.DB./DB.AF.DB., pDB-
.DTm.DB./AB.AF.DB., or a mixture of pDB.DTm.DB./DB.a AF.DB. and pD-
B.DTm.DB./AB.a AF.DB. as previously reported (1) except that cytomix
was used (2). Electroporated parasites (2 3 108) were injected intrave-
nously into phenylhydrazine-treated naive Wistar rats, and py-
rimethamine treatment was begun (1). 9–10 days later when para-
sitemias had reached $0.5%, 100 ml of blood was transferred
intraperitoneally to six Swiss mice, and pyrimethamine pressure main-
tained was. 4–6 days after infection, when parasitemias had reached
5%, mice were bled by cardiac puncture to provide parasites for DNA
analysis and cryopreserved stocks. Parasites for analyses detailed be-
low were derived from Swiss mice that had been infected with cryopre-
served parasites and maintained under pyrimethamine pressure.
Analysis of Transfected Parasites
Leukocytes were removed from infected blood (Plasmodipur, Eurodi-
agnostica, Apeldoorn, The Netherlands) that was then either used
directly or cultured for a further 12–24 h in an atmosphere of 5% O2, 5%
CO2, 90% N2 (21). Parasite DNA and RNA was isolated (Gentra Sys-
tems Inc., Minneapolis, MN) according to the manufacturer’s instruc-
tions. Western blots following reduced SDS-polyacrylamide gel electro-
phoresis (Phast-system, 10–15% gradient gel, Amersham Pharmacia
Biotech, Uppsala, Sweden) used parasite stages that had been enriched
by Nycodenz centrifugation (21) and stored at 280 °C.
For purification of gametocytes, rats were infected with 108 in vitro
matured, Nycodenz-purified schizont-infected red cells isolated from an
infected rat at 1% parasitemia. 27 h after infection rats were bled, and
gametocytes were Nycodenz purified (21).
Rat mAb Development and in Vitro Inhibition of Invasion Assay
The pan-specific AMA-1 rat mAb 28G2dc1 recognizes a linear deter-
minant at the highly conserved C terminus and immunoprecipitates
both the full-length 83-kDa and processed 66-kDa forms of PF83/
AMA-1; rat mAb 58F8dc1 recognizes a linear determinant in the N-
terminal region and only immunoprecipitates the 83-kDa form (13).
Additional mAbs were developed from rats that had been immunized
with recombinant PF83/AMA-1 (22) essentially as described (13).
For in vitro inhibition of invasion assays, purified IgG was incubated
in triplicate with schizont-infected red blood cells at a parasitemia of
0.04% to 0.1% in 96-well flat-bottomed plates (Costar, Cambridge, MA)
in a total volume of 100 ml (1.0–1.5% hematocrit) (T0h). After two cycles
of invasion (T65h), 25 ml of RPMI 1640 containing 10% human serum,
and [3H]hypoxanthine (Amersham International, ’s-Hertogenbosch,
The Netherlands) was added to each well to yield a final concentration
of 20 mCi ml21. Parasites were harvested (T87h) onto glass fiber filters
using a Skatron cell harvester (Suffolk, UK), and [3H]hypoxanthine
incorporation was determined by liquid scintillation spectrometry. Par-
asite growth inhibition, reported as a percentage, was determined as
follows: ((mean cpmcontrol 2 mean cpmexperimental)/mean cpmcontrol) 3
100. The cpm for red blood cells alone was subtracted from all averages
prior to determining the percentage of inhibition. All analyses of sta-
tistical significance were performed by Student’s t test.
IFA and Immunoelectron Microscopy
Methanol-fixed thin films were prepared and used for IFA as de-
scribed previously (13), and in some experiments mAbs that had been
directly succinamide-conjugated with fluorophores (Molecular Probes,
Leiden, The Netherlands) were used according to the manufacturer’s
instructions. Slides were mounted in anti-fade (5% (w/v) 1,4-diazobicy-
clo[2.2.2 octane], 10 mM Tris-HCl, pH 8, 90% glycerol) to which 4,6-
diamidino-2-phenylindole (23) at a final concentration of 1.9 mM was
added. Photographs were taken with a Photometrics CH250 cooled CCD
camera mounted on a Leica DMRXA microscope. Digital images that
were generated were all treated identically. IFA on fresh unfixed ga-
metes was performed with a mixture of 28G2dc1, 58F8dc1, and 4G2dc1
mAb culture supernatants on homogenized mid-guts of Anopheles ste-
phensi at various times after they had fed on infected Swiss mice (24).
Immunoelectron microscopy was performed on gametocytes and schi-
zonts transfected with PF83/AMA-1 expressed under the P. berghei
dhfr-ts promoter. Cells harvested as for IFA were fixed (20 min on ice in
0.1% (v/v) double-distilled glutaraldehyde in RPMI), washed four times
in fresh ice-cold RPMI, then dehydrated in a series of ethanols cooled
progressively from 0 to 220 °C, infiltrated with LR White Resin over-
night, and polymerized at room temperature under indirect ultraviolet
light for 48 h (25). Sectioned material was stained using mAb 58F8dc1
at 25 mg ml21 and secondary goat anti-rat antibodies labeled with
10-nm gold. Grids were post-stained for 2 min in 2% aqueous uranyl
acetate. Controls were parasites transfected with pf83/ama-1 ORF in
the reverse orientation.
ELISA
Total IgG—ELISA plates (Greiner, Labortechnik, Solingen, Ger-
many) were coated overnight at 14 °C with 100 ng ml21 PF83-7G8-1
(22) in phosphate-buffered saline/0.02% NaN3, pH 7.4, and blocked with
3% bovine serum albumin/phosphate-buffered saline. Dilutions of
mouse sera in antibody buffer (0.5% bovine serum albumin/phosphate-
buffered saline, pH 8.0) were tested in triplicate, and bound IgG was
detected by goat anti-mouse IgG coupled to alkaline phosphatase as
described previously (26).
Competition ELISA—ELISA plates were prepared as above. Rat
mAb 4G2dc1 was coupled to alkaline phosphatase (Sigma-Aldrich N.V./
S.A., Bornem, Belgium) (27). Duplicate mouse sera (diluted 1:100) and
mAb 4G2dc1 (30 mg ml21) in an optimized concentration of alkaline
phosphatase coupled 4G2dc1 in antibody buffer were incubated in wells
coated with PF83-7G8-1 (90 min, 37 °C). The plates were washed,
substrate was added (2 h), and the A405 was determined. Inhibition of
4G2dc1 binding was calculated using the average OD reading for each
group of mice relative to the average OD reading for a pool of normal
Swiss mouse serum.
Immunization of Mice with Transfected P. berghei
To assess specific antibody production in animals infected with
transfected parasites, infected mice received regular pyrimethamine
treatment to maintain plasmids in the parasite population. Parasitemia
was controlled when it reached 1% by sulfadiazine treatment (10 mg/
liter drinking water) for 2–4 days (28) until parasites were barely
detectable by Giemsa thin film. Mice were chloroquine-treated after 5
weeks to kill all remaining parasites and allow recovery and were
reinfected with the same transfected parasites 3 weeks later (2 3 107
schizonts/mouse intraperitoneally). To counteract bone marrow sup-
pression induced by pyrimethamine, these mice received folinic acid
intraperitoneally once per week (400 mg/kg).
RESULTS
Transfected P. berghei Parasites Express PF83/AMA-1—The
rodent malaria P. berghei was transfected with constructs that
were designed to express PF83/AMA-1 controlled by two differ-
ent promoters. The selection cassette was based on the ability
to confer resistance to pyrimethamine, and for this an engi-
neered T. gondii dhfr-ts gene was chosen because of its high
resistance levels and the reduced likelihood of unwanted ho-
mologous integration (3). To allow easier manipulation of the
selection cassette T. gondii dhfr-ts was mutagenized to remove
EcoRI and KpnI sites. This mutant T. gondii dhfr-ts was
flanked by P. berghei dhfr-ts control regions. In addition to the
selectable marker cassette, vectors pDB.DTm.DB./AB.AF.DB.
(Fig. 1A) and pDB.DTm.DB./DB.AF.DB. (Fig. 1B) respectively
employed the pb66/ama-1 promoter or the P. berghei dhfr-ts
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promoter to control PF83/AMA-1 expression. Transfection of P.
berghei schizont-infected red blood cells with these constructs
yielded pyrimethamine-resistant parasites. Southern blot, po-
lymerase chain reaction, and plasmid rescue analyses showed
that these parasites contained the T. gondii dhfr-ts gene, indi-
cating that the T. gondii DHFR-TS is active in P. berghei and
that the mutagenesis of T. gondii dhfr-ts had no detrimental
effects on DHFR-TS expression (data not shown).
Pyrimethamine-resistant transgenic P. berghei parasite pop-
ulations obtained from mice were matured in vitro and ana-
lyzed for the presence of the AMA-1 protein of the human
malaria P. falciparum. IFA with mAb 58F8dc1 specific for the
N-terminal region of PF83/AMA-1 reacted strongly with recom-
binant P. berghei but not with control P. berghei parasites,
indicating that PF83/AMA-1 was expressed.
Developmental Stage-specific Trans-species Expression of
PF83/AMA-1 Is Promoter-mediated—Northern blots of total
RNA isolated from 1 3 107 rings, schizonts, or gametocytes and
probed with pf83/ama-1 showed high levels of a 2.3-kb mRNA
in schizonts and gametocytes of parasites transfected with the
construct containing the P. berghei dhfr-ts promoter, whereas
under control of the pb66/ama-1 promoter, transcription was
only observed in schizonts (Fig. 2A, lanes 2, 3, and 5). The weak
hybridization signal in lane 9 (gametocytes transfected with
the pb66 promoter construct) can be accounted for by slight
contamination of this preparation with mature schizonts (ver-
ified in Giemsa-stained thin films). No transcripts were de-
tected in ring stage parasites nor in parasites transfected with
pf83/ama-1 in the reverse orientation. Hybridization of these
Northerns with a T. gondii dhfr-ts probe showed transcription
of the selectable marker gene in all schizont and gametocyte
lanes but not in the lanes from ring stage parasites.
Western blot analysis using a pan-specific mAb (28G2dc1)
that reacts with a linear determinant present in all Plasmo-
dium AMA-1 molecules identified to date revealed expression
of PF83/AMA-1 as a full-length 83-kDa protein in mature schi-
zonts. No expression was detected in ring stage parasites,
irrespective of the promoter used to drive expression (Fig. 2B,
lanes 2 and 5). In addition, expression controlled by the dhfr-ts
promoter was detected in gametocytes (Fig. 2B, lane 3). Anal-
ogous to the situation in P. falciparum (13), N-terminal proteo-
lytic processing to a form of approximately 66 kDa was ob-
served (Fig. 2B, lanes 2 and 5). This processed form migrated as
the slightly larger molecule in a 66-kDa doublet, the other
component of which was authentic P. berghei AMA-1, which
was also reactive with mAb 28G2dc1 (Fig. 2B, lanes 2, 5, and 8).
As expected authentic P. berghei AMA-1 expression was re-
stricted to schizonts. Confirmation of this expression profile for
full-length PF83/AMA-1 expression was obtained through re-
activity of the 83-kDa AMA-1 with the N-terminal mAb
58F8dc1, which does not react with P. berghei AMA-1 (data not
shown). Interestingly, P. berghei gametocytes that express
PF83/AMA-1 under control of P. berghei dhfr-ts also showed
processing to the 66-kDa form (Fig. 2B, lane 3). No PF83/
AMA-1 expression was evident when P. berghei was trans-
fected with constructs containing pf83/ama-1 in the reverse
orientation (Fig. 2B, lanes 7, 8, and 9). The weak 66-kDa signal
in the gametocyte lanes 6 and 9 can be accounted for by minor
contamination of the gametocyte preparations with mature
schizonts.
Trans-species Expressed PF83/AMA-1 Attains a Functional
Conformation—AMA-1 contains multiple disulfide links (29)
that generate species-specific epitopes that are critical to vac-
cine efficacy (11, 17) and protein function (30). Rat mAbs ca-
pable of blocking P. falciparum AMA-1 function were selected
from a panel of mAbs characterized by recognition of reduction-
sensitive, native, parasite determinants present on both full-
length and processed PF83/AMA-1. Thus all mAbs in this panel
immunoprecipitated both full-length (83-kDa) and processed
(66-kDa) forms of PF83/AMA-1 from Triton X-100 extracts of
metabolically radiolabeled P. falciparum schizonts but were
not reactive with Western blots of P. falciparum schizonts. One
of these mAbs, 4G2dc1 (IgG2a) consistently inhibited asexual
P. falciparum multiplication in vitro (by 60–70% compared
with control mAbs of the same isotype). This mAb reacted by
IFA with all ten P. falciparum strains of diverse geographical
origin analyzed to date. Critically, 4G2dc1 also recognized
transfected P. berghei parasites by IFA when PF83/AMA-1 was
expressed under both pb66 and pb-dhfr promoter control.
Temporal Regulation of Trans-species PF83/AMA-1 Expres-
sion—A more detailed analysis of PF83/AMA-1 protein expres-
sion in transgenic P. berghei was performed by IFA with mAb
4G2dc1. Parasites transfected with pDB.DTm.DB./AB.AF.DB.,
FIG. 1. Plasmid constructs used for the trans-species expres-
sion of PF83/AMA-1 in P. berghei. Plasmids contained Tg dhfr-ts
controlled by P. berghei dhfr-ts 59 and 39 regions to enable selection of
transfected parasites on the basis of pyrimethamine resistance. PF83/
AMA-1 expression was under control of a 1.5-kb 59 region of pb66/
ama-1 (pDB.DTm.DB./AB.AF.DB.) (A) or a 2.2-kb 59 region of P. berghei
dhfr-ts (pDB.DTm.DB./DB.AF.DB.) (B) and 39 P. berghei dhfr-ts regions.
Constructs pDB.DTm.DB./AB.a AF.DB. and pDB.DTm.DB./DB.a AF.DB. are
identical except that the pf83/ama-1 ORF is in reversed orientation.
FIG. 2. Northern blot (A) and Western blot (B) analyses of
transfected P. berghei parasites. Parasites were transfected with
vector pDB.DTm.DB./DB.AF.DB. (lanes 1–3), vector pDB.DTm.DB./
AB.AF.DB. (lanes 4–6), or a mixture of vectors pDB.DTm.DB./AB.a AF.DB.
and pDB.DTm.DB./DB.a AF.DB. (lanes 7–9). Parasites were purified at
ring stage (lanes 1, 4, and 7), schizont stage (lanes 2, 5, and 8), and
gametocyte stage of development (lanes 3, 6, and 9). A, total RNA was
isolated from purified parasite populations and fractionated on a 1%
agarose-formaldehyde gel (RNA from 107 parasites/lane), blotted onto a
nylon membrane, and probed with a 32P-labeled pf83/ama-1 ectodo-
main probe under stringent conditions. The 2.3-kb mRNA (lanes 2, 3,
and 5) mirrors PF83/AMA-1 protein expression. B, extracts were frac-
tionated by SDS-polyacrylamide gel electrophoresis under reducing
conditions (5 3 105 parasite equivalents/lane) and blotted onto a nitro-
cellulose membrane. The blot was reacted with the panspecific mAb
28G2dc1. 83- and 66-kDa forms of PF83/AMA-1 are evident in trans-
fected schizonts (lanes 2 and 5) and in gametocytes when under dhfr-
ts-promoter control (lane 3). Control transfected schizonts only express
the 66-kDa Pb66/AMA-1 (lane 8).
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using the pb66/ama-1 promoter to control PF83/AMA-1 ex-
pression, expressed PF83/AMA-1 only in maturing schizonts
with six or more nuclei (Fig. 3A). In contrast, in parasites
obtained after transfection with pDB.DTm.DB./DB.AF.DB., using
the dhfr-ts promoter to control expression, PF83/AMA-1 was
initially observed in maturing trophozoites and during onset of
schizogony and could be detected throughout schizont develop-
ment (Fig. 3B). PF83/AMA-1 expression in native conformation
was also evident in gametocytes of both sexes when under
control of the dhfr-ts promoter (Fig. 3C). IFA analysis of acti-
vated gametes in homogenized mosquito mid-gut revealed
PF83/AMA-1 expression 1 h after a blood meal but not 24 h
after feeding of the mosquitoes (data not shown). Parasites
obtained after transfection with the construct containing the
pb66/ama-1 promoter consistently failed to show expression of
PF83/AMA-1 in gametocytes and gametes (data not shown).
Subcellular Localization of Trans-species Expressed PF83/
AMA-1 Is Promoter-dependent—Quantitation of PF83/AMA-1
expression under control of the pb66/ama-1 promoter by count-
ing fluorescence patterns in 1000 free merozoites yielded PF83/
AMA-1 localization entirely to the apex of 95% of the merozo-
ites (Fig. 3D). In contrast, expression under control of the
dhfr-ts promoter yielded in 85% of the merozoites a strong
circumferential and cytoplasmic staining in addition to occa-
sional weak apical staining (Fig. 3E). This difference in local-
ization is already evident in maturing schizonts (Fig. 3, A and
B), where the protein when expressed under ama-1 promoter
control is apparently associated with developing organelles,
whereas under dhfr promoter control, a much more diffuse
localization is evident.
Immunoelectron microscopy analysis of expression under the
dhfr-ts promoter shows that PF83/AMA-1 is distributed patch-
ily in the cytoplasm of merozoites, and in some rhoptries, it
localizes to the rhoptry body but is not found in micronemes or
dense granules (Fig. 3F). In maturing gametocytes the protein
is associated with the endoplasmic reticulum network (not
shown). IFA analyses of gametes performed on unfixed mate-
rial 1 h after mosquito feeding revealed PF83/AMA-1 expres-
sion at the gamete surface.
Immunization with Transfected P. berghei Parasites Yields
High Titer Antibodies to PF83/AMA-1—To determine whether
P. berghei parasites that expressed PF83/AMA-1 could induce
an immune response against PF83/AMA-1, two groups of Swiss
mice were infected with P. berghei transfected either with
mixed pDB.DTm.DB./DB.AF.DB. and pDB.DTm.DB./AB.AF.DB.
(forward pf83/ama-1) or with mixed pDB.DTm.DB./DB.a AF.DB.
and pDB.DTm.DB./AB.a AF.DB. (reverse pf83/ama-1). Sulfadi-
azine modulation of parasite growth was used to permit two
sequential peaks of parasitemia of approximately 1% (28). Par-
asitemia peaks were observed at the end of the first week after
infection and at the beginning of the third week after infection.
A second infection was given in week 9. Expression of PF83/
AMA-1 was monitored by IFA on parasites that were obtained
from infected mice and matured (18 h) in vitro and was evident
throughout the experiment. Antibodies reactive with PF83/
AMA-1 were already detected at week 4 as determined by
ELISA on pooled sera (end point titer 1:20,000; data not
shown), and by week 11 antibody titers were .1:100,000 (Fig.
4), whereas in the control group titers of approximately
1:10,000 were observed. This control group reactivity can be
explained by cross-reactive antibodies induced by P. berghei
AMA-1. To unequivocally demonstrate the appearance of PF83/
AMA-1 specific reactivity and determine whether the func-
tional epitope defined by mAb 4G2dc1 was recognized, a com-
petition ELISA was performed. Only antibodies of mice
FIG. 3. Immunofluorescent and immunoelectron microscopic analyses of transfected P. berghei parasites expressing PF83/AMA-1.
For IFA, methanol-fixed thin films were reacted with the PF83/AMA-1-specific mAb 4G2dc1, and parasite nuclei were stained with 4,6-diamidino-
2-phenylindole. A, P. berghei schizont-infected red cells at various stages of development (six and twelve nuclei, and segmented schizont)
expressing PF83/AMA-1 under control of the pb66/ama-1 promoter. PF83/AMA-1 expression is barely visible at the six-nucleus stage (arrow), but
prominent at the twelve-nucleus stage (middle parasite) and in segmented schizonts (top parasite). B, P. berghei mature schizont-infected red cell
expressing PF83/AMA-1 under control of the dhfr-ts promoter, showing high level expression. Similar expression was observed in mature
trophozoites (not shown). C, P. berghei gametocyte expressing PF83/AMA-1 under control of the dhfr-ts promoter. D and E, free merozoites
expressing PF83/AMA-1 under control of the pb66/ama-1 promoter showing apically restricted fluorescence (D) and under control of the dhfr-ts
promoter showing predominantly circumferential and cytoplasmic fluorescence (E). F, electron microscopic section through a developing merozoite
within a schizont of P. berghei expressing PF83/AMA-1 under control of the dhfr-ts promoter. Note the rhoptry body staining along with adjacent
regions of cytoplasm. The section was immunostained with 58F8dc1 (specific for the N terminus of PF83/AMA-1), and secondary antibodies were
labeled with 10-nm gold (magnification, 364,000).
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immunized with transfected P. berghei parasites that were
expressing PF83/AMA-1 effectively competed with mAb
4G2dc1 (Fig. 4), demonstrating that components of the immune
response were directed against a critical functional epitope of
PF83/AMA-1.
DISCUSSION
The development of transgene expression systems for ma-
laria will allow detailed study of parasite cell biology. Mecha-
nisms underlying drug resistance, protein trafficking, and mo-
lecular function can be explored in greater depth than
previously possible, and manipulation of parasite phenotype
for evaluation of attenuated vaccines, for example toward
higher immunogenicity and lower pathogenicity, becomes fea-
sible. Here we report on the first studies of trans-species ex-
pression of a human malaria vaccine candidate antigen and
show (i) that the protein is expressed in a conformationally and
functionally relevant form, (ii) that depending on the time of
expression it is differentially routed within the developing par-
asite, and (iii) that it is highly immunogenic within the context
of a rodent malaria parasite. These studies employed an asex-
ual blood stage vaccine candidate, AMA-1, a single copy gene
that has a well defined, tightly controlled, stage-specific ex-
pression pattern (13, 14, 31) and contains targeting signals for
the rhoptries, organelles involved in red cell invasion. Vaccine
experiments to date have shown that deletion mutants of
AMA-1 are not induced under immune pressure (15, 16), indi-
cating it is an essential molecule. As a prelude to AMA-1
knockout experiments, which we expect to be lethal because
the parasite genome during asexual phase development is hap-
loid, we have developed trans-species complementation capa-
bilities for this molecule. In this study two promoters controlled
PF83/AMA-1 expression, the authentic P. berghei ama-1 pro-
moter, and the P. berghei dhfr-ts promoter. Both promoters
induced expression of conformationally intact, full-length
PF83/AMA-1. However, the time of appearance and the subcel-
lular distribution of the protein were substantially different.
PF83/AMA-1 conformation was assessed by reactivity with a
mAb (4G2dc1) that inhibited P. falciparum invasion of eryth-
rocytes in vitro. This mAb is reactive with an invariant, reduc-
tion-sensitive conformational and functional epitope and pro-
vides a new tool to assess the correct conformation of P.
falciparum AMA-1 molecules.
Trans-species PF83/AMA-1 expression under control of the
pb66/ama-1 promoter was analogous to authentic PF83/
AMA-1 expression in P. falciparum (13), restricted to schizonts
with six or more nuclei. This demonstrates that the 1.5 kb of
the pb66/ama-1 upstream region present in the expression
construct contains sufficient information to drive stage-specific
expression of PF83/AMA-1. Under P. berghei dhfr-ts promoter
control, PF83/AMA-1 was expressed throughout schizogony as
well as in gametocytes, coordinated with DHFR-TS expression
from the genomic copy (32) in developmental stages where
DNA synthesis is ongoing. Although, because eight male ga-
metes are produced from each microgametocyte, it was not
surprising that under dhfr-ts promoter control PF83/AMA-1
was expressed in male gametocytes, approximately 30% of
PF83/AMA-1-expressing gametocytes were female. It remains
to be determined whether these results indicate that DHFR-TS
is also normally synthesized in female gametocytes (perhaps in
preparation for post-fertilization DNA synthesis) or whether
the dhfr-ts driven expression observed is a consequence of loss
of transcriptional control because of incomplete 59 elements or
loss of chromosomal positioning. Despite prolonged exposure
we found no evidence for dhfr-ts mRNA transcripts in ring
stages, in contrast to a previous report (32).
The timing of expression markedly influenced the subcellu-
lar localization of PF83/AMA-1. When expressed under the
ama-1 promoter, the protein is routed to the rhoptries, as is
authentic AMA-1 (13, 14, 33). In contrast, expression controlled
by the dhfr-ts promoter during the onset of schizogony, when
rhoptries are absent, as well as in gametes that do not contain
rhoptries, results in targeting to the parasite surface as well as
in a cytoplasmic localization, as is evident from both IFA and
immunoelectron microscopy data. When rhoptries are being
formed, dhfr-ts-controlled PF83/AMA-1 is also routed to the
rhoptries but is notably localized to the rhoptry body (Fig. 3F)
rather than authentically localized in the rhoptry neck (14). At
this stage cytoplasmic localization is also detected, but the fate
of this cytoplasmically localized protein is not yet clear. Addi-
tional immunoelectron microscopy studies are currently being
performed to more closely define the localization of authentic
and trans-species expressed AMA-1 in relation to the promoter
used to drive expression. Exchanging putative signal and tar-
geting sequences in future transfection experiments will start
to unravel the trafficking of rhoptry and other organellar pro-
teins to their final destination.
Proteolytic processing of PF83/AMA-1 from an 83- to a 66-
kDa form occurred both in schizonts and in gametocytes, sug-
gesting that the processing is mediated by a common parasite
protease that is not restricted to the rhoptry. This processing
event does not occur in P. berghei AMA-1 because it is synthe-
sized de novo as a 66-kDa molecule, as are all other AMA-1
forms reported to date. This extra N-terminal region, present
only in P. falciparum, is of unknown function, but its cleavage
seems to be associated with capacity for merozoite invasion of
red cells (13).
Although there are significant obstacles to the development
of vaccines based on the malaria parasite itself, it is possible
that effective vaccines may ultimately be based upon attenu-
ated parasites or upon nonpathogenic species that are geneti-
cally modified to carry heterologous target proteins. To evalu-
ate the immunogenicity of PF83/AMA-1 expressed in the
context of a P. berghei infection, mice were chronically infected
with transgenic P. berghei parasites. The observed responses
and the fine specificity thereof demonstrate that trans-species
expression of the human P. falciparum antigen PF83/AMA-1 in
FIG. 4. ELISA titration of individual mouse sera 11 weeks after
infection with transfected P. berghei. Mice were infected with P.
berghei transfected with pf83/ama-1 (thick lines) or with reverse ORF
pf83/ama-1 (thin lines), allowed to experience two waves of parasitemia
over a 4-week period, and were finally boosted with 2 3 107 schizonts at
week 8. Titration was performed using recombinant full-length PF83/
AMA-1 as solid phase antigen. The inset shows results of a competition
ELISA demonstrating that only IgG from the experimental group of
mice competes with mAb 4G2dc1 for binding to PF83/AMA-1 (.45%
inhibition of binding). Lines over the bars indicate standard deviations.
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P. berghei can elicit a strong immune response directed against
a functionally important region of this molecule. Given the
protection induced in primate models after AMA-1 vaccination
(15, 16), it will be interesting to evaluate whether trans-species
expression can provide protection against a challenge with a
heterologous parasite species. This is not possible in the system
described here because rodents are not susceptible to infection
with P. falciparum. However, as a prelude to such studies in
other systems we have recently shown that expression of
AMA-1 from other primate malaria species is feasible in P.
knowlesi,2 a parasite of relatively broad host specificity.
In summary, we have demonstrated drug-selectable trans-
species expression of a second gene (in addition to the select-
able marker) in a malaria parasite. P. falciparum AMA-1 ex-
pression in P. berghei under control of the stage-specific P.
berghei pb66/ama-1 promoter or the more constitutive P.
berghei dhfr-ts promoter resulted in a timing and subsequent
subcellular localization of PF83/AMA-1, which markedly dif-
fered between the two promoters. In addition, antibodies to a
critical functional determinant of PF83/AMA-1 were elicited in
mice, emphasizing strong immunogenicity of the trans-species
expressed protein.
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